Article
APOC3, coronary disease, and complexities of Mendelian randomization.
Cell metabolism - 2 Sept 2014
Cohen Jonathan C, Stender Stefan, Hobbs Helen H
Abstract excerpt
Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.